The therapeutic efficacy of combining PVT1-104aa inhibition with anti-PD-L1 therapy was tested in vivo.<h4>Results</h4>PVT1-104aa was significantly overexpressed in CRC and correlated with poor patient prognosis. This evidence concerns the gene PVT1 and colorectal carcinoma.